



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: May 20, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, May 20, 2022, inter-alia, has:

1. Considered and approved the Audited Financial Results for the Quarter and year ended March 31, 2022.
2. Recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting.

The Financials Results will be published in newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 04:30 p.m.

We hereby enclose the following:

1. Copy of the Audited Financial Results of the Company for the quarter and year ended March 31, 2022;
2. Copy of the Auditors Report;
3. Declaration w.r.t. audit report with unmodified opinion;

Kindly take the above said information on your records.

Thanking you,



Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.
Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.
Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.
Creating true values that bind global health

Yours faithfully,

For Supriya Lifescience Limited



Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 |E-mail: supriya@supriyalifescience.com |Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

SUPRIYA LIFESCIENCE LIMITED

CIN: L51900MH2008PLC180452


Registered Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: supriya@supriyalifescience.com; Website: www.supriyalifescience.com

Part I - Statement of Standalone Audited Financial Results for the Quarter & Year Ended March 31, 2022

Rs. in Millions, except per share data

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
		31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
		Audited*	Unaudited	Unaudited	Audited*	Audited
	Income					
I	Revenue from Operations	1,812.69	1,216.04	1,321.07	5,300.49	3,912.45
II	Other Income	38.55	8.38	15.02	75.77	49.77
III	Total Income	1,851.24	1,224.41	1,336.09	5,376.26	3,962.21
2	Expenses					
	a) Cost of Materials Consumed	382.42	722.27	414.96	1,988.30	1,405.71
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in inventories of finished goods, work in progress & stock in trade.	325.89	(304.35)	(117.78)	(30.26)	(124.45)
	d) Employee benefit expenses	128.69	184.29	92.89	490.78	327.61
	e) Finance Cost	10.17	11.49	12.42	41.98	40.80
	f) Depreciation & amortisation expense	25.79	25.99	17.84	101.18	67.61
	g) Other expenditure	223.46	184.03	259.34	711.82	571.83
IV	Total Expenses	1,096.43	823.72	679.67	3,303.81	2,289.11
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	754.81	400.70	656.42	2,072.45	1,673.10
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	754.81	400.70	656.42	2,072.45	1,673.10
VIII	Tax Expense					
	a) Current Tax	184.45	124.16	174.85	521.89	430.22
	b) Deferred Tax	108.25	(119.86)	(3.50)	32.46	6.94
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	462.11	396.40	485.07	1,518.10	1,235.93
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	462.11	396.40	485.07	1,518.10	1,235.93
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	1.55	(5.27)	0.59	(4.22)	(1.66)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.37)	1.33	(0.15)	1.08	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	463.28	392.46	485.51	1,514.95	1,234.69
XVI	Earnings per equity Share (for continuing operation):					
	(1) Basic (In ₹)	5.74	4.93	6.63	18.86	16.89
	(2) Diluted (In ₹)	5.74	4.93	6.63	18.86	16.89
XVII	Earnings per equity Share (for discontinued operation):					
	(1) Basic (In ₹)	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):					
	(1) Basic (In ₹)	5.74	4.93	6.63	18.86	16.89
	(2) Diluted (In ₹)	5.74	4.93	6.63	18.86	16.89



SUPRIYA LIFESCIENCE LIMITED

CIN: L51900MH2008PLC180452

Registered Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: supriya@supriyalifescience.com; Website: www.supriyalifescience.com

Audited Balance Sheet as at March 31, 2022

Rs. in Millions, except per share data

Particulars	For the Year ended March 31, 2022 (Audited)	For the Year ended March 31, 2021 (Audited)
ASSETS		
Non-current assets		
(i) Property, plant and equipment	1,824.68	969.53
(ii) Right to Use Asset	57.97	14.72
(iii) Capital Work in progress	434.09	787.88
(iv) Intangible Assets	15.09	16.13
(v) Financial Assets		
-Investments	0.53	0.53
-Loans and Advances	-	-
(vi) Other Non- Current Assets	39.84	11.25
Total Non-current assets	2,372.18	1,800.03
Current assets		
(i) Inventories	923.12	724.80
(ii) Financial Assets		
-Loans and Advances	5.74	5.38
-Trade receivables	1,151.83	735.00
-Cash and cash equivalents	1,657.76	434.98
-Bank balances other than (iii) above	621.32	457.79
-Other Financial Assets	60.32	30.16
(iii) Other current assets	555.34	266.51
Total Current Assets	4,975.44	2,654.63
TOTAL ASSETS	7,347.62	4,454.66
EQUITY AND LIABILITIES		
EQUITY		
(i) Equity share capital	160.97	146.37
(ii) Other equity	5,995.91	2,539.46
Total Equity	6,156.88	2,685.83
LIABILITIES		
Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	-	-
-Lease Liabilities	52.95	20.65
-Other financial liabilities	-	194.86
(ii) Provisions	29.31	13.01
(iii) Deferred tax Liabilities	111.49	80.11
Total Non-Current Liabilities	193.76	308.64
Current liabilities		
(i) Financial liabilities		
-Borrowings	212.95	701.30
-Lease Liabilities	8.25	
-Trade payables	489.72	510.22
-Other financial liabilities	7.94	5.66
(ii) Provisions	4.12	9.06
(iii) Other current liabilities	274.01	233.96
Total Current Liabilities	996.99	1,460.19
TOTAL EQUITY AND LIABILITIES	7,347.62	4,454.66



SUPRIYA LIFESCIENCE LIMITED

CIN: L51900MH2008PLC180452


Registered Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: supriya@supriyalifescience.com; Website: www.supriyalifescience.com

Audited Cash flow statement for the year ended March 31, 2022

Rs. in Millions, except per share data

(All amounts in Indian ₹ million, except as otherwise stated)	For the Year ended March 31, 2022 (Audited)	For the Year ended March 31, 2021 (Audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	2,072.45	1,673.10
Adjustments for		
Depreciation and Amortization	101.18	67.61
Interest Income	(70.70)	(49.79)
Interest on Lease Liability	(3.36)	(4.50)
Finance Cost	41.59	40.57
Provision for Bad debts		-
Operating profit before working capital changes	2,141.16	1,726.99
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	(416.83)	(218.70)
Inventories	(198.32)	(230.22)
Other Current Assets	(288.83)	(79.23)
Loans and Advances	(30.53)	(1.45)
Other Non Current Assets	(28.59)	12.76
	(963.10)	(516.83)
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	(20.50)	16.53
Short term / Long term provisions	7.14	0.89
Other Financial Liabilities	(194.86)	4.66
Other Current liabilities	127.79	(143.25)
	(80.43)	(121.17)
(Income tax paid)/net of refund	(609.62)	(299.94)
Net Cash generated from Operating Activities	488.01	789.05
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(599.04)	(482.41)
(Purchase)/ Sale of Investments		
Sale of fixed Assets	0.82	14.40
Net Cash generated/(outflow) from Investing Activities	(598.22)	(468.01)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Shares	2,000.00	
Increase/(Decrease) in Long term borrowings	-	(23.93)
Increase/(Decrease) in Short term borrowing	(486.07)	(92.73)
Finance Cost	(36.58)	(38.74)
Dividend Paid	(43.91)	(39.56)
Interest Income	70.70	49.79
Repayment of Lease liability	(7.63)	
Net Cash generated from Financing Activities	1,496.52	(145.16)
Net Increase/(Decrease) in Cash and Cash equivalents	1,386.31	175.88
Cash and Cash Equivalents at the end of previous period	922.93	747.05
Cash and Cash Equivalents as at the end of the reporting period	2,309.24	922.93



Notes:-

1. The Audited Standalone financial results of the Company for the quarter & year ended March 31, 2022 have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above Audited standalone financial results of the Company for the quarter & year ended March 31, 2022 have been reviewed by the Audit Committee on May 20, 2022 and thereafter approved by the Board of Directors at their meeting held on May 20, 2022.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
- *4. The Statutory Auditor have submitted Audit Report on the above Audited Financial Results for Quarter & Year ended March 31, 2022.
5. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.

Place :- Mumbai
Date :- May 20, 2022



**For and on behalf of the board of directors of
Supriya Lifescience Limited**

A handwritten signature in blue ink, appearing to read "Satish Wagh".

**Satish Wagh
Chairman & Managing Director
DIN: 01456982**

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

YOUR REF.:

OUR REF.:

INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUPRIYA LIFESTYLE LIMITED

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **SUPRIYA LIFESTYLE LIMITED** ("the Company"), for the three months and year ended March 31, 2022 ("the Statement"/"Standalone Financial Results"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2022.



Basis for Opinion

We conducted our audit of these Standalone Financial Results in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim Condensed Standalone Financial Statements for the three months and year ended March 31, 2022. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Ind AS 34 prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial

Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the



circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For,

Kakaria and Associates LLP

Chartered Accountants.

FRN: 104558W/ W100601



CA. Ujwal K. Kakaria

Partner

Membership No. – 035416

Place: - Mumbai

Date: - 20th May, 2022

UDIN: - 22035416AJHZIJ9815



Date: May 20, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

**Sub: Declaration pursuant to Regulation 33 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

In terms of the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors of the Company M/s. Kakaria & Associates LLP, Chartered Accountants (FRN: 104558W/W100601) have issued an Audit Report with unmodified opinion in respect of Audited Financial Results for the quarter and financial Year ended March 31, 2022.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,
For Supriya Lifescience Limited


Ashish Nayak
Chief Financial Officer

